 Multiple Sclerosis MS is a neuroinflammatory and degenerative central nervous system disorder. The majority of patients have an early relapsing-remitting course. Standard treatment for an MS-relapse is intravenous methylprednisolone IVMP, typically 1000 mg daily for 3 days. Despite IVMP treatment, 40 of MS patients experience residual deficits after an MS-relapse. Potential risk factors for poor relapse recovery remain unclear. 